A listing of the exact species content for any particular lot of Yellow Jacket or Wasp venom protein may be obtained by calling Technical Services at Jubilant HollisterStier LLC, (800) 992-1120.įinal containers of sterile freeze-dried venom products are sealed under vacuum. Diagnosis should be based on individual venoms.īecause of the difficulty in collecting all species of Yellow Jacket and Wasp, the venom raw materials for these two insects may vary in species composition from lot to lot. The Mixed Vespid venom protein is for immunotherapy only, not for diagnosis. The reconstituted single venom products are intended for subcutaneous injection for immunotherapy and percutaneous use for diagnosis. Mixed Vespid venom protein (Yellow Jacket, Yellow Hornet and White-Faced Hornet) is also available. Hymenoptera Venom Products available are sterile freeze-dried venom of Honey Bee ( Apis mellifera) and venom protein of Yellow Jacket ( Vespula sp.), Yellow Hornet ( Dolichovespula arenaria), White-Faced Hornet ( Dolichovespula maculata) and Wasp ( Polistes sp.). Refer also to CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and OVERDOSAGE for further discussion. This product must never be injected intravenously.
#Bee venom skin
The only approved method for diagnosing insect sting allergic patients for immunization is by skin testing.
Immunotherapy for insect sting allergy should be given to those patients who have experienced significant systemic reactions (for detailed description of symptoms see INDICATIONS AND USAGE and ADVERSE REACTIONS) from insect stings and who demonstrate hypersensitivity by skin testing with these products. Patients on beta blockers may be more reactive to allergens given for testing or treatment and may be unresponsive to the usual doses of epinephrine used to treat allergic reactions. Patients should be treated only if the benefit of treatment outweighs the risks. These patients may also be more refractory to the normal allergy treatment regimen. Patients with cardiovascular diseases and/or pulmonary diseases such as symptomatic unstable, steroid-dependent asthma, and/or those who are receiving cardiovascular drugs such as beta blockers, may be at higher risk for severe adverse reactions. See ADVERSE REACTION, Section 3, of the instruction for information regarding adverse event reporting.Īll patients should have available an Emergency Anaphylaxis Kit containing epinephrine and be instructed in its use for emergency treatment of possible systemic reactions occurring at times after the patient has departed the testing or treatment premises. Patients should be instructed to recognize adverse reaction symptoms, observed in the office for at least 30 minutes after skin testing or treatment, and cautioned to contact the physician's office if symptoms occur. (1) Therefore, emergency measures and personnel trained in their use must be available immediately in the event of such a reaction. Hymenoptera venom extracts may potentially elicit a severe life-threatening systemic reaction, rarely resulting in death. The researchers reproduced the melittin synthetically and found it mirrored the majority of the anti-cancer effects of the honeybee venom.This product is intended for use only by licensed medical personnel experienced in administering allergenic extracts and trained to provide immediate emergency treatment in the event of a life-threatening reaction.
It really needs quite a bit of research to be approved by the Therapeutic Goods Administration," she said.Ĭiara Duffy, from Western Australia's Harry Perkins Institute of Medical Research, said a component of the venom called melittin had the killing effect. "We would like to partner with a university to get some medical studies done on the efficacy of the treatment. Ms McQueen-Richardson said the chance to partner with a university to tap into institutional knowledge would be helpful in creating a pathway to see if the venom could be regulated and approved in Australia. The study also found when the venom's main component was combined with existing chemotherapy drugs, it was extremely efficient at reducing tumour growth in mice. "Rather than just doing the same old, same old, let's look at ways we can diversify," Ms McQueen-Richardson said.Ī study published in the Nature Precision Oncology journal last year found venom from honeybees could rapidly kill aggressive and hard-to-treat breast cancer cells. The technology, developed by company Whale Labs, is a bee venom collection device that doesn't harm the bees. She said her business HoneyBee Hives, which operates from Coutts Crossing, would be using Queensland-invented technology to see if bee venom could be used for both cosmetic and therapeutic purposes.
0 kommentar(er)
